Glaxo cuts prices on AIDS drugs in developing countries

GlaxoSmithKline, the maker of anti-HIV medications 3TC, AZT, Ziagen, Combivir, Trizivir, and Agenerase, announced last week that the company will cut the wholesale price of its AIDS drugs sold to developing nations by up to 33% off already discounted prices. The company began offering discounted anti-HIV drugs in sub-Saharan African and other developing nations two years ago, but international AIDS activists have said the prices still remain too high for most HIV-positive people to afford. "We are delivering on our commitment to review prices for these essential medicines for patients in 63 of the world's poorest countries," said Glaxo CEO Jean-Pierre Garnier. The company also announced price cuts for its anti-malarial medications by up to 38%.